Krosyl Pharmaceuticals Private Limited

Krosyl Pharmaceuticals Private Limited, established on January 5, 2015, is a privately held pharmaceutical company headquartered in Vadodara, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24100GJ2015PTC081717. With an authorized and paid-up capital of ₹5 million, Krosyl Pharmaceuticals operates in the manufacturing sector, focusing on the production of pharmaceutical finished formulations.

The company's mission is to become a global healthcare organization recognized for its integrated healthcare and pharmaceutical solutions through innovation, quality, and competence. Krosyl Pharmaceuticals aims to provide high-quality, affordable medicines to support patients in need, striving to improve access and affordability, create healthier communities, and promote a healthy mind, body, and environment worldwide.

Krosyl Pharmaceuticals operates manufacturing facilities in Vadodara, Gujarat, India. The company emphasizes maintaining high-quality standards in its manufacturing processes, adhering to Good Manufacturing Practice (GMP) guidelines. Krosyl Pharmaceuticals is certified by the World Health Organization (WHO) for GMP compliance, ISO 9001:2008, and Good Laboratory Practice (GLP), ensuring the production of safe and effective pharmaceutical products.

The leadership team at Krosyl Pharmaceuticals includes:

• Parth Joshi: Founder and CEO, leading the company's strategic direction and operations.

• Amit Prabhudas Patel: Director, appointed on July 30, 2024, contributing to the company's governance and strategic initiatives.

• Nilesh Prajapati: Director, serving since the company's inception on January 5, 2015, providing leadership and oversight.

• Parth Rameshkumar Joshi: Director, also serving since January 5, 2015, involved in the company's strategic decision-making processes.

• Maulik R Joshi: Director, appointed on July 30, 2024, playing a role in the company's strategic planning and execution.

Krosyl Pharmaceuticals has established a presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained certifications such as WHO-GMP and ISO 9001:2008, which are recognized by regulatory authorities in these regions. These certifications facilitate market access and demonstrate the company's commitment to maintaining high-quality manufacturing standards.

Krosyl Pharmaceuticals has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its ability to meet international quality standards, facilitating access to these markets. By offering affordable and high-quality pharmaceutical products, Krosyl Pharmaceuticals aims to address the healthcare needs of diverse populations in these regions.

Krosyl Pharmaceuticals' geographic strategy involves a balanced approach, focusing on both established and emerging markets. The company's WHO-GMP and ISO 9001:2008 certifications support its expansion efforts, enabling it to navigate regulatory requirements effectively. By diversifying its market presence, Krosyl Pharmaceuticals mitigates concentration risks and positions itself for sustainable growth in the global pharmaceutical industry.

As of March 2026, specific details regarding Krosyl Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on maintaining WHO-GMP and ISO 9001:2008 certifications indicates a commitment to quality standards recognized by international regulatory bodies.

Krosyl Pharmaceuticals holds WHO-GMP certification, demonstrating compliance with international manufacturing standards. This certification is recognized by the European Union, facilitating market access within EU member states. The company's adherence to these standards underscores its commitment to producing high-quality pharmaceutical products.

Krosyl Pharmaceuticals operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's WHO-GMP and ISO 9001:2008 certifications align with CDSCO's requirements for pharmaceutical manufacturing. These certifications reflect the company's adherence to national and international quality standards, ensuring the safety and efficacy of its products.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Krosyl Pharmaceuticals. The company's WHO-GMP and ISO 9001:2008 certifications suggest a proactive approach to maintaining compliance with regulatory standards.

Krosyl Pharmaceuticals operates in a competitive landscape, with several companies offering similar pharmaceutical products. While specific market share data is not publicly available, the company's WHO-GMP and ISO 9001:2008 certifications position it favorably in the market. These certifications enhance the company's credibility and appeal to customers seeking high-quality pharmaceutical products.

Krosyl Pharmaceuticals differentiates itself through its commitment to innovation, quality, and affordability. The company's WHO-GMP and ISO 9001:2008 certifications reflect its adherence to international manufacturing standards. By focusing on providing high-quality pharmaceutical products at affordable prices, Krosyl Pharmaceuticals aims to build a healthier world for people.

Krosyl Pharmaceuticals' strategic direction centers on becoming a global healthcare organization recognized for its integrated pharmaceutical solutions. The company's focus on innovation, quality, and competence supports its mission to provide high-quality, affordable medicines. By maintaining WHO-GMP and ISO 9001:2008 certifications, Krosyl Pharmaceuticals demonstrates its commitment to meeting international standards and addressing diverse medical needs.

Krosyl Pharmaceuticals maintains a strong track record in pharmaceutical manufacturing, as evidenced by its WHO-GMP and ISO 9001:2008 certifications. The company's commitment to quality and compliance with international standards indicates reliability in its manufacturing processes. While specific export volumes and consistency data are not publicly available, the company's certifications suggest a focus on delivering high-quality products to its customers.

Importers should verify the following certifications when considering Krosyl Pharmaceuticals as a supplier:

• WHO-GMP Certification: Indicates compliance with international manufacturing standards. Verification can be done through the World Health Organization's official channels.

• ISO 9001:2008 Certification: Demonstrates adherence to quality management systems. Verification can be conducted through the International Organization for Standardization's official website.

When conducting due diligence on Krosyl Pharmaceuticals, consider the following steps:

• Verify Certifications: Confirm the validity of WHO-GMP and ISO 9001:2008 certifications through official channels.

• Assess Financial Health: Review the company's financial statements for the latest fiscal year to evaluate profitability and financial stability.

• Evaluate Regulatory Compliance: Ensure the company adheres to relevant regulatory standards in target markets.

• Review Product Portfolio: Examine the range and quality of products offered to ensure they meet your requirements.

• Check References: Seek feedback from existing clients or partners to gauge reliability and service quality.

By following this checklist, importers can make informed decisions regarding potential partnerships with Krosyl Pharmaceuticals.